WILMINGTON, Mass., Nov. 24, 2014 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB: IMSC), a leading manufacturer of
explosives trace detection (ETD) and drugs trace detection
solutions for homeland security applications, today announced the
Company has won a competitive contract for 18 QS-H150s to be
shipped to a county in the EMEA region (Europe, the Middle
East and Africa). The
country which made the purchase is a North Atlantic Treaty Alliance
(NATO) member nation and will use Implant Sciences' handheld
explosive trace detectors in military applications.
"Our sales team has done a great job of getting the QS-H150 in
front of this important customer for a sizeable contact.
Ultimately, based on feedback from the customer, we believe that
Implant Sciences was awarded this contract due to the outstanding
performance of our QS-H150. In a direct, side by side comparison,
our handheld device proved superior over competing systems in
detecting trace levels of a range of explosives," stated Implant
Sciences' Vice President of Global Sales and Marketing, Dr.
Darryl Jones. "We're proud of the
consistent, high performance capabilities of our explosives trace
detectors."
About the QS-H150 Handheld Explosives Trace Detector
The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology,
providing fast, accurate detection of trace amounts of a wide
variety of military, commercial, and homemade explosives. Built
with no radioactive materials and featuring a low-maintenance,
self-calibrating, and self-clearing design, the QS-H150 provides
very high levels of operational availability. The QS-H150 has been
proven to perform well in a wide variety of temperatures and
challenging environments, from humid jungles to dry, sand swept
deserts.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 50 countries worldwide. Implant
Sciences is only the third manufacturer, and the sole
American-owned company, to currently have an ETD system named as a
Qualified Product by the US Transportation Security Administration.
The Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., STAC in France, the German
Ministry of the Interior, and the Ministry of Public Safety in
China. It also received a GSN 2013
Homeland Security Award for "Best Explosives Detection
Solution". All Implant Sciences products are recognized as
Qualified Anti-Terrorism Technologies by the Department of Homeland
Security. For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking
statements," as that term is defined in the Private Securities
Litigation Reform Act of 1995. Such statements are based on
management's current expectations and are subject to risks and
uncertainties that could cause the Company's actual results to
differ materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
we will be required to repay all of our indebtedness to our secured
lenders by March 31, 2015; if we are
unable to satisfy our obligations and to raise additional capital
to fund operations, our secured lenders may seize our assets and
our business may fail; we continue to incur substantial operating
losses and may never be profitable; our independent registered
public accounting firm has expressed substantial doubt as to our
ability to continue as a going concern; there is no guaranty that
U.S. or foreign government and law enforcement agencies or
commercial consumers will purchase any of our explosives detection
products or that any new products we may develop will be accepted
by the Transportation Security Administration or by such other
governments, agencies or consumers; economic, political and other
risks associated with international sales and operations could
adversely affect our sales; liability claims related to our
products or our handling of hazardous materials could damage our
reputation and have a material adverse effect on our financial
results; our business is subject to intense competition; our
markets are subject to rapid technology change and our success will
depend on our ability to develop and introduce new products; we may
not be able to retain our management and key employees or identify,
hire and retain additional personnel as needed; we may not be able
to enforce our patent and other intellectual property rights or
operate without infringing on the proprietary rights of others; and
other risks and uncertainties described in our filings with the
Securities and Exchange Commission, including our most recent Forms
10-K, 10-Q and 8-K. Such statements are based on management's
current expectations and assumptions which could differ materially
from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
SOURCE Implant Sciences Corporation